A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing Disulfiram

Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of 6% and is projected to be the second leading cause of cancer death by 2030, underscoring the urgency to develop new strategies to improve current therapeutic modalities for PDAC. Targeting pancreatic cancer stem cells (PCSCs), which are resistant to radiation and chemotherapy, is a promising strategy. A novel approach which can be readily clinically translated is to repurpose disulfiram (DSF), a drug for treating alcoholism, to target PCSCs.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2x2vKg1
via IFTTT